Graphical analysis of data from the Official US Vaccine Side Effects Database (VAERS) found that a very small percentage of certain lot numbers of Pfizer and Moderna’s Covid-19 vaccines were responsible for most side effects and deaths in the United States.
By comparison, the influenza vaccination campaign had less harmful consequences than the Covid 19 vaccination campaign, it is said. More alarming is that the “deadly” lots were distributed widely across the United States whilst other “benign” lots were sent to a few specific locations.
Analysis showed that in 4 289 batches distributed to 12 or fewer states, there were few reports of adverse reactions and hospitalizations and no deaths. By contrast, 13 lots of Pfizer and Moderna vials shipped to many US states had reported the most adverse reactions and deaths.
Some 96 percent of Pfizer vaccines were therefore “safe”. The 2 828 reported deaths are due to only 4 percent of Pfizer lots. Moderna had no death records for 95 percent of lots. The 2 603 reported deaths are therefore due to 5 percent of the batches.
Authorities look the other way
Why have the US authorities never inspected these deaths caused by certain batches of Pfizer/Moderna? According to the authors, the Covid-19 vaccination campaign in the US was significantly more “deadly” than the influenza campaign. Another Pfizer whistleblower from a Kansas manufacturing facility noted that “people are being made to sign off on things that normally they wouldn’t, and then they wonder why their own employees won’t take it”.
Comparison with influenza vaccination
The analysis relates to reports submitted to VAERS by October 15, 2021 about undesirable side effects or deaths after being jabbed with Moderna or Pfizer products. The information on influenza was used as control data. There were 1608 adverse side effects, 15 deaths and 73 hospitalizations for a total of 494 batch numbers reported. Accordingly, there were no concentrated abnormalities in the influenza batches. The standard batch size for Covid-19 shots is assumed to be 1000 vials or 6000 jabs.
Thousands of injury reports on a batch
At Pfizer, there were 171 463 reports of adverse reactions, 2 828 deaths and 14 262 hospitalizations linked to 4 522 batch numbers. With the Pfizer treatment there were 106 times as many side effects, 189 times as many deaths and 195 times as many hospitalizations as with the influenza vaccines. The highest number of adverse reactions for a single Pfizer lot number was 3 563 (26 for the influenza vaccination).
Moderna got off even worse: There were 4 967 negative reports for a single batch. At Moderna 188 998 adverse reactions, 2 603 deaths and 10 225 hospitalizations were reported – this was linked to 5 510 batches. Compared to influenza, there were 188 times more side effects, 174 times more deaths and 140 times more hospitalizations.
Data in Pfizer registration study was falsified
A whistleblower has meanwhile revealed that the data from the registration study for Pfizer’s Corona vaccination had been falsified, as reported in the prestigious British Medical Journal (BMJ). The “blinding” of the patients had been lifted and unwanted side effects had only been followed up reluctantly. The employees in charge of quality control were overwhelmed by the sheer volume of problems identified. Even the mainstream media has been reporting on this information bombshell.
Pfizer had violated both scientific and ethical standards in terms of laboratory management, patient safety and data integrity.
There were also problems entering data for severe side effects. The patients were inadequately monitored and the follow-up protocols were poor. Laboratory samples were mislabeled in part, according to the allegations of the whistleblower. According to Ventavia Regional Director Brook Jackson, she filed a complaint with the US Medicines Agency. Jackson had 15 years of clinical research management experience before she joined Ventavia.
Since the institute did not take care of these problems, she began to take photos with her smartphone to document the grievances. These images show, for example, that study participants’ identification numbers are noted on the vaccine packaging and these had been lying around openly.
The FDA did not seem particularly interested in Jackson’s distressing information. During the FDA’s emergency vaccine approval meeting, the issues at Ventavia were not even mentioned. The next day the vaccine was approved by the FDA.
Two other Ventavia employees with many years of experience have confirmed Jackson’s allegations to the BMJ. However, they wanted to remain anonymous because they feared losing their jobs.
At a German press conference, the head of the Robert Koch Institute, Lothar Wieler, was asked about the article in the BMJ and said: “If that’s true, that’s unacceptable.” Health Minister Jens Spahn, on the other hand, ignored the information.
EMA documents also show serious quality concerns
Are there impurities in the mRNA vaccines that cannot be assigned to a conspiracy theory? In the first comprehensive evaluation and approval documents of the European Medicines Agency (EMA), the texts reflect the problems of a new technology for drugs that, despite numerous uncertainties, weaknesses and improvisations, were publicly released.
To date, Pfizer/BioNTech have failed to even meet significant EMA requirements that are considered to be the main requirements for conditional approval. (Assessment Report February 19, 2021 and updated product description, October 14, 2021, p. 39)
Published on December 21 last year and updated on February 19, the little-known identifying document is a joint product of the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC) and the EMA’s Epidemic Task Force (ETF). It was not translated into other European languages, as is usual with EU Commission documents. This contradicts the public transparency obligation. A large part of the European population therefore has no access to it.
The quality problems of the vaccine are the focus of the 140-page text. Topics such as product inconsistency, the different batch qualities or possible contamination including unknown health effects were discussed in a highly complex work process. Test and control procedures were defined and some possible dangers characterized as subliminal, especially with two authorized doses.
The EMA experts repeatedly criticized pharmaceutical companies for insufficient information and a lack of studies as well as concerns over carcinogenic substances.
The EMA assessment report on p. 50 states that in the manufacturing process of the lipid component ALC-0159 the substances classified as carcinogens acetamide, dioxin and polyethylene oxide can arise as unwanted by-products. All three substances are on the official German Insurance Risk list of carcinogenic germ cell mutagens and substances, known as the DGUV list. According to the EMA, however, it is “expected” that they will only occur in harmless quantities after a double dose [author inquiry to the EMA, No. ASK-98501 and ASK-98500].
According to a press release on October 4, the EMA did not allow a third booster dose from 18 years of age until six months after the second dose at the earliest due to “limited safety data”.